Pharmaceutical Executive-09-01-2004

Pharmaceutical Executive

September 22, 2004

TOC

Pharmaceutical Executive

September 01, 2004

There's a reason the political parties have formally embraced the Hispanic market this election year: The number of US Hispanic adults (age 18 and older) is topping off at almost 25 million in 2004. And there's a reason the parties are using culturally relevant messaging and Spanish-language content: 40 percent of US Hispanics are foreign born.

Pharmaceutical Executive

September 01, 2004

The key is to convert raw data into actionable intelligence that can enhance operations and improve decision making.

Pharmaceutical Executive
Features

September 01, 2004

Unfortunately, companies sometimes violate the public trust by issuing false or misleading statements about FDA-related issues, such as the progress of FDA's pre-market review. When we identify suspected misstatements, we have a new process to bring them to the attention of the SEC staff as quickly and efficiently as possible." Then FDA Commissioner Mark McClellan issued that statement in a February press release.

Pharmaceutical Executive

Pharma marketing appears to operate in a world of its own. When US ad expenditures dipped in 2001, pharma's spend marched steadily on. (See "A Different Drum.") Now, as the ad industry celebrates the quadrennial coincidence of the Olympics and the US presidential campaign, is pharma taking notice? "Not really," says Anne Devereaux, chief integration officer at BBDO.

Pharmaceutical Executive

September 01, 2004

September Table of Contents

Pharmaceutical Executive
Features

September 01, 2004

The dynamic that drove the profits out of infant formula is about to be repeated-this time in pharma.

Pharmaceutical Executive
Features

September 01, 2004

Electronic product codes (EPCs) provide a nearly perfect solution for many of pharma's problems with counterfeiting, diversion, theft, and the like.

Pharmaceutical Executive
Features

September 01, 2004

Synta is in a very unusual position: Two Big Pharmas have paved the way with proteins, while the small biotech follows with a pill.

Pharmaceutical Executive
Features

September 01, 2004

Single drugs for single indications are hard to find. Here's how to get around that.

Pharmaceutical Executive
Features

September 01, 2004

Future savings from specialty pharmacies will come at pharma companies' expense.

Pharmaceutical Executive
Features

September 01, 2004

Pharm Exec asked a group of research experts what they think are the essential components in putting data to work. Here’s what they said.

Pharmaceutical Executive
World News

September 01, 2004

Between January and June this year, 45 UK vendors capitulated to the activists and stopped supplying pharma companies.